ArticleHuman vaccines & immunotherapeutics2025
Impact of the COVID-19 pandemic on the timeliness of pertussis-containing vaccination: A cohort study in Shanghai, China.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Resurgence of Pertussis in Tuscany (Italy): A Six-Year Retrospective Epidemiological Analysis.Pathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The COVID-19 epidemic has significantly disrupted routine childhood immunization programs. This study assesses the impact of different COVID-19 prevalence phases on immunization coverage and timeliness in Shanghai, China. We employed a retrospective cohort design, encompassing children born between September 1, 2018, and August 30, 2023. Children were categorized into three COVID-19 phases based on their expected vaccination dates: baseline period, epidemic period, and pre/post-epidemic period. Kaplan-Meier estimators were utilized to ascertain the cumulative vaccination probabilities, with differences tested using the log-rank method. A multivariate Cox proportional hazards model was conducted to assess the impact of COVID-19 phases on vaccination timeliness. Vaccination timeliness significantly declined when the vaccination window coincided with an epidemic period, particularly for older children and during heightened epidemic activity. The probability of timely vaccination at 2 months was 0.89 (95% CI: 0.86-0.92) in the baseline period and 0.53 (95% CI: 0.51-0.55) in the epidemic period, compared to the pre/post-epidemic period. At 3 months, the probability of timely vaccination decreased 12% (HR = 0.88, 95% CI 0.86-0.90) and 49% (HR = 0.51, 95% CI 0.49-0.53), respectively. Similarly, for vaccinations scheduled at 4 months, the probabilities of timely vaccination were 0.87 (95% CI 0.85-0.89) and 0.49 (95% CI 0.47-0.51) times. At 5 months, the probabilities declined 9% (HR = 0.91, 95% CI 0.87-0.94) and 57% (HR = 0.43, 95% CI 0.40-0.46), correspondingly. Our study assessed the notable decline of vaccination timeliness during epidemic periods, highlighting the need for targeted strategies to mitigate disruptions in routine childhood immunization services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.